Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR: MSCs for DNA Repair in Critical COVID-19
NCT04898088Completed
- Sponsor
- Dr. Sadi Konuk Training and Research Hospital
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of mesenchymal stem cells in COVID-19 pneumonia (2 arms), sponsored by Dr. Sadi Konuk Training and Research Hospital. Primary endpoints: Expression of PARP1 gene at 6 months, Expression of genes ATM, RAD51, RAD52 and WRN at 6 months and 2 more. Started Jan 2020; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04898088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898088.